Arpeggio has developed a platform to drug oncogenic transcription factors. Our automated laboratory screens tens of thousands of molecules for changes in TF activity using nascent RNA sequencing. With the world's largest database linking nascent-RNA to small molecules, we use machine learning to identify patterns between molecular structure and transcriptomic impact, unlocking new chemistry for targets like TFs. Our initial pipeline is focused on combating drug resistance in cancer.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):